JBIO
Jade BiosciencesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that JADE101 delivers credible Phase 1 biomarker and PK data in Q2 2026, enabling a clean transition into IgAN patient studies while JADE201 also enters the clinic on schedule. If Jade executes on both assets, investors may start valuing it as a multi-program autoimmune platform with enough capital to reach several inflection points.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +27.0.
What can break
Early biomarker success in healthy volunteers may not translate into patient efficacy in IgAN or other autoimmune indications.
Momentum
89
Value
41
Sentiment
47
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.00 · Bull $30.00 · Bear $14.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $45.89
Why
Momentum89 · Δ7d +27.0
Value41 · Δ7d -0.1
Sentiment47 · Δ7d -2.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
89
26% active weight
Current posture
7d trendImproving
Δ7d
+27.0
Δ21d
+71.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
47
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.5
Δ21d
+4.0
Why this grade
Composite grade B. Momentum 88.9 / Value 41.1 / Sentiment 47.4
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.27B
Beta
0.88
Shares Out
60.86M
P/E (TTM) · Derived
-5.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.07
Rev YoY
-
EPS YoY
-99.9%
Gross Margin
-
Op Margin
-
Net Debt
-$335.43M
Current Ratio
14.29
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology

